On the stock market since 2020, it operates in the world of health and science. It has 1,546 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 10% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price looks reasonable next to what the company earns.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 81% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $418.8M a year. A small number, but proof the product has real buyers.
There is $189.4M in the vault; even if every debt were paid off, $178.0M would remain.
Over the last 12 months, company executives reported 56 buys and 48 sells. Management buying with its own money is usually read as a good sign.
A loss of $1.6M against $418.8M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 49/100.
On our five-subject report card, CERT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CERT is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.